Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Vittorio, Luigi"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Carlo Pallotto, Maurizio Fiorio, Antonio D'Avolio, Alessio Sgrelli, Franco Baldelli, Giovanni Di Perri, Giuseppe Vittorio Luigi De Socio
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 1 (2014)
Today very little is known about tigecycline penetration into cerebrospinal fluid (CSF). We report, in a clinical setting, tigecycline concentration, and the area under concentration-time curve (AUC) - both in blood and in CSF - of a patient affecte
Externí odkaz:
https://doaj.org/article/1a4afdbe80cb4bde89110c66123533de
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 3, Iss 1, Pp e2011010-e2011010 (2011)
Hepatitis B virus (HBV) infection constitutes a serious global health problem. Nowadays there are divergent data regarding the use of antiviral drugs to treat acute hepatitis B. We present here a case of a 62-year-old man affected by severe acute hep
Externí odkaz:
https://doaj.org/article/6bb4fe9d49f74c89aa9f1fc51feaa1d0
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 3, Iss 1, Pp e2011010-e2011010 (2011)
Hepatitis B virus (HBV) infection constitutes a serious global health problem. Nowadays there are divergent data regarding the use of antiviral drugs to treat acute hepatitis B. We present here a case of a 62-year-old man affected by severe acute hep
Externí odkaz:
https://doaj.org/article/e9dca9e6eebc46868c6f1b31df2a3c1b
Autor:
William P. Harris, Max W. Sung, Dirk Waldschmidt, Ying A. Wang, Tatiane Cristine Ishida, Richard D. Kim, Udo Mueller, Barbara J. Brennan, Vittorio Luigi Garosi, Hong Zebger-Gong, Peter R. Galle, Anthony B. El-Khoueiry, Roniel Cabrera
Publikováno v:
Journal of Clinical Oncology. 39:4078-4078
4078 Background: REG, a multikinase inhibitor, and PEMBRO, an anti-PD-1 mAb, are approved as monotherapies in advanced HCC after progression on sorafenib. This phase 1b dose-finding study investigated first-line REG plus PEMBRO in advanced HCC. Metho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dc3fd045a213221bdbb1ffc8b13fd002
https://doi.org/10.1200/jco.2021.39.15_suppl.4078
https://doi.org/10.1200/jco.2021.39.15_suppl.4078
Autor:
Uwe M. Martens, Piotr Saramak, Hanno Riess, Stefano Cascinu, Katrin Roth, Wollf Schmiegel, John Bridgewater, Prabhu Rajagopalan, Marc Peeters, Henrik Seidel, Barrett H. Childs, Jean-Luc Van Laethem, Jacek Jassem, Marius Giurescu, Svein Dueland, Bohuslav Melichar, Vittorio Luigi Garosi, Paul Ross, Colin D. Weekes, Patrick Michl, Michael Teufel, Anke Schulz, Alberto Zaniboni, David Van Brummelen, Michael Haas
Publikováno v:
Targeted oncology
Background: Activating KRAS mutations are reported in up to 90% of pancreatic cancers. Refametinib potently inhibits MEK1/2, part of the MAPK signaling pathway. This phase I/II study evaluated the safety and efficacy of refametinib plus gemcitabine i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb7b5d7aa8ee952eeec33dfc4f153b0a
https://hdl.handle.net/10067/1526720151162165141
https://hdl.handle.net/10067/1526720151162165141
Autor:
De Socio, Giuseppe Vittorio Luigi1 giuseppedesocio@yahoo.it, Sgrelli, Alessio1, Tosti, Andrea1, Baldelli, Franco1
Publikováno v:
Mediterranean Journal of Hematology & Infectious Diseases. 2011, Vol. 3 Issue 1, p1-4. 4p.
Autor:
Josep Tabernero, Iain R. Macpherson, Eric Van Cutsem, Al B. Benson, Carmen Guillen Ponce, Andrea Wagner, Dirk Strumberg, Fernando Rivera, Mark P Saunders, Julia Grunert, Stefano Cascinu, Fortunato Ciardiello, Guillem Argiles, Vittorio Luigi Garosi, John Zalcberg, Claus-Henning Köhne, Alberto Sobrero
Background The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed. This study investigated regorafenib plus modified FOLFOX (mFOLFOX6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74008246b01558bb0b523f9f4c3c6c75
http://www.journals.elsevier.com/european-journal-of-cancer/
http://www.journals.elsevier.com/european-journal-of-cancer/
Publikováno v:
Reconstructive Surgery of the Rectum, Anus and Perineum ISBN: 9781848824126
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a82e4d9e4fd122cc490d2676c9dfc8b
https://doi.org/10.1007/978-1-84882-413-3_2
https://doi.org/10.1007/978-1-84882-413-3_2
Autor:
Parruti, Giustino, Polilli, Ennio, De Socio, Giuseppe Vittorio Luigi, Sozio, Federica, Marconi, Patrizia, Soddu, Viviana, Dalessandro, Margherita, Celesia, Benedetto Maurizio, Pellicanò, Giovanni, Madeddu, Giordano, Vecchiet, Jacopo, Di Masi, Francesco, Mazzotta, Elena, Ursini, Tamara, Martinelli, Canio, Vitiello, Paola, Bonfanti, Paolo, Nigro, Luciano, Mura, Maria Stella Anna, Antinori, Andrea, Ricci, Elena, Manzoli, Lamberto
Purpose: The evidence suggesting increased HAART efficacy over time comes from randomized trials or cohort studies. This retrospective multicenter survey aimed to assess the variation over time in the efficacy and tolerability of first-line HAART reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1389::591832f32ca56733013a4c34fb04ef20
http://eprints.uniss.it/7671/
http://eprints.uniss.it/7671/